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Abstract  
 
Dopamine (DA) controls many vital physiological functions and is critically involved in several 
neuropsychiatric disorders such as schizophrenia and attention deficit hyperactivity disorder 
(ADHD). The major function of the plasma membrane dopamine transporter (DAT) is the rapid 
uptake of released DA into presynaptic nerve terminals leading to control of both the 
extracellular levels of DA and the intracellular stores of DA. Here, we present a newly 
developed strain of rats (DAT-knockout, DAT-KO rats) in which the gene encoding the DAT 
has been disrupted by using zinc finger nuclease technology (ZFN). DAT-KO rats develop 
normally but weigh less than heterozygote and wild-type rats and demonstrate pronounced 
spontaneous locomotor hyperactivity. While striatal extracellular DA lifetime and 
concentrations are significantly increased, the total tissue content of DA is markedly decreased 
demonstrating the key role of DAT in the control of DA neurotransmission. Hyperactivity of 
DAT-KO rats can be counteracted by amphetamine (AMPH), methylphenidate and a few other 
compounds exerting inhibitory action on DA-dependent hyperactivity. DAT-KO rats also 
demonstrate a deficit in working memory and sensorimotor gating tests and show strong 
dysregulation in frontostriatal BDNF function. DAT-KO rats could provide a novel translational 
model for human diseases involving aberrant DA function and/or mutations affecting the DAT 
or related regulatory mechanisms.  
 
Significance statement   
 
Here, we present a newly developed strain of rats in which the gene encoding the DAT has 
been disrupted (DAT-KO rats).  DAT-KO rats weigh less than controls and demonstrate 
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pronounced spontaneous locomotor hyperactivity. While striatal extracellular DA lifetime 
and concentrations are increased, the total tissue content of DA is markedly decreased 
demonstrating the key role of DAT in the control of DA neurotransmission. Hyperactivity 
of DAT-KO rats can be counteracted by amphetamine (AMPH), methylphenidate and a 
few other compounds exerting inhibitory action on DA-dependent hyperactivity. DAT-KO 
rats also demonstrate a deficit in working and show strong dysregulation in frontostriatal 
BDNF function. DAT-KO rats could provide a novel translational model for human 
diseases involving aberrant DA functions.
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Introduction 
 
Dopaminergic innervations are prominent in the brain and the dopamine (DA) system exerts 
modulatory control of motivation, reward, cognition and locomotion (Carlsson, 1987; Gainetdinov, 
2008). Concentration of DA in the synaptic cleft is the primary determinant of DA signaling 
intensity. The key regulatory element of DA neurotransmission is the DAT, belonging to a family 
of plasma membrane transporters of solute carrier family 6 (SLC6). The DAT controls levels of 
extracellular DA and maintains DA stores by transporting released DA back into neurons. DAT is 
the well-established target of many drugs of abuse and neurotoxins (Saunders et al., 2000; Kahlig et 
al., 2006; Wheeler et al., 2015; Siciliano et al., 2016). Amphetamine (AMPH) and cocaine (COC) 
are psychostimulants that are able to induce euphoria and hyperactivity by increasing extracellular 
DA via interaction with the DAT. 	
The DAT knockout (KO) mouse model generated in 1996 by Giros and colleagues (Giros et al., 
1996). DAT-KO mice display a distinct behavioural phenotype: they are hyperactive, display 
certain cognitive deficits and sleep dysregulation (Gainetdinov et al., 1999; Spielewoy et al., 2000). 
The hyperdopaminergic phenotype of DAT-KO mice have provided a simple model of 
hyperdopaminergic function in which the effects of various pharmacological agents affecting DA 
related functions and behaviours have been evaluated. In particular, they are extremely sensitive to 
D2 dopamine receptor blockers and antipsychotics such as haloperidol and show a paradoxical 
inhibitory response to psychostimulants AMPH and methylphenidate (MPH) (Gainetdinov et al., 
1999; Spielewoy et al., 2000; Carboni et al., 2001). 	
DAT-KO mice have provided important information on the pathological consequences of aberrant 
DA function. DAT-KO mice are believed to best model Attention Deficit Hyperactive Disorders 
(ADHD) endophenotypes by demonstrating spontaneous hyperactivity, deficits in cognitive tests 
and anti-hyperkinetic responses to psychostimulants used in ADHD treatments (Gainetdinov and 
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Caron, 2000, 2001). At the same time, DAT-KO animals have provided numerous advances in 
understanding the pathology and pharmacology of other dopamine-related brain disorders, such as 
schizophrenia (Gainetdinov et al., 2001; Wong et al., 2012, 2015), bipolar disorder (Beaulieu et al., 
2005, 2005), Parkinson’s disease (Cyr et al., 2003; Sotnikova et al., 2005) and addiction (Rocha et 
al., 1998). Notably, several patients diagnosed with ADHD, bipolar disorder and parkinsonism 
(Vaughan and Foster, 2013; Hansen et al., 2014) have rare coding variants of the SLC6A3 DAT 
gene. Recently, DAT-KO mice were used to evaluate the efficacy of adenoviral therapy for 
Dopamine Transporter Deficiency Syndrome (DTDS) (Illiano et al., 2017), a newly recognized 
Parkinsonian-like condition with earlier hyperkinetic stage, whose symptomatology is directly 
caused by an impaired DAT functioning due to loss-of-function mutations found in SLC6A3 DAT 
gene (Kurian et al., 2009, 2011; Ng et al., 2014; Yildiz et al., 2017). 	
The recent progress in the development of gene editing approaches has made possible to perform 
such studies in genetically altered rats. Beyond obvious advantages of rat models, such as larger 
brain size for surgery and electrophysiological recordings as well as their closer physiological 
similarity to humans, rats have a much wider repertoire of well-established behavioural approaches 
to investigate cognitive functions that are critical for modelling neuropsychiatric conditions.  
Here we present a new model of DAT deficiency, DAT-KO rats, generated by using zinc-finger 
nucleases (ZFN) technology (Geurts et al., 2009; Brown et al., 2013) used for the elimination of the 
DAT gene. The current study describes detailed neurochemical, behavioural, and pharmacological 
characterization of this model	 that could open new perspectives in understanding pathology and 
pharmacology of human diseases involving aberrant DA function and/or mutations affecting the 
DAT or DAT-related regulatory mechanisms.	
 
 
Materials and methods  
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Animals  
 
ZFN design, construction, in vitro validation, microinjection and founder selection were performed 
as previously described (Geurts et al., 2009; Carbery et al., 2010). The ZFN Target site was: 
CTCATCAACCCGCCACAGAcaccaGTGGAGGCTCAAGAG in the Exon 2 of Slc6a3 gene 
(NCBI Gene ID: 24898; Genomic NCBI Ref Seq: NC_005100.3; mRNA NCBI Ref Seq: 
NM_012694.2). The knockout rat lines were created in the outbred Wistar Han background at 
SAGE Labs. Adult littermate rats were housed by genotype in groups of 3 to 4 with free access to 
tap water and standard pellet food. They were kept at 22°C and on a 12/12 h light/dark cycle (lights 
on 0700–1900 h). All experiments were conducted in compliance with the Italian Ministry of 
Health (DL 116/92; DL 111/94-B) and European Community (86/609/EEC) directives regulating 
animal research. All efforts were made to minimize animal suffering and to reduce the number of 
animals used.	
Genotyping was performed by PCR followed by enzymatic digestion with BtsI MutI (New England 
Biolabs (Milan, Italy).  
 
 
Real-Time PCR 
Animals were sacrificed and PreFrontal Cortex (PFC), dorsolateral striatum (DLStr) and midbrain 
were dissected and dissociated for 15 minutes at 37ºC with Pronase enzyme (Sigma) in Hank's 
Balanced Salt Solution (HBSS, Invitrogen). Brain samples were triturated with three glass pipettes 
of decreasing tip diameter and centrifuged at 900 rpm at room temperature for 5 minutes. To 
remove excess debris, cell pellets were resuspended in HBSS and filtered through a 70 µm mesh 
(BD Falcon, #352350). Cells-to-CT kit (Life Technology) was used to produce DNase I digested 
cell lysates and perform cDNA synthesis, according to manufacturer's instructions. cDNAs were 
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used for Taqman singleplex PCR. To prevent false positive originating from genomic DNA, we 
used negative control samples without reverse transcriptase. All reagents were supplied by Applied 
Biosystems. PCR master mix contained 1x Taqman Universal PCR Master Mix, 1x Gene 
Expression Assay mix, and 1µl cDNA for a total volume of 20µl. The following Gene Expression 
Assays were used: Drd2 (Assay ID Rn01452984_m1), Drd1a (Assay ID Rn00569454_m1), TH 
Assay ID Rn00562500_m1); Gapdh (Assay ID Rn01775763_g1) and Hprt (Assay ID 
Rn01527840_m1). Samples were run in three replicates for each Gene Expression Assay. PCR 
reactions were carried out on a 7900 Thermal Cycler (Applied Biosystems) with 40 cycles of 95ºC 
for 15 seconds and 60 ºC for 1 minute. CT values for each gene were normalized to CT values for 
GAPDH and HPRT to obtain a relative expression level for each replicate and the three replicates 
were averaged together.  
For BDNF analysis, an aliquot of total RNA of each sample (n=5 WT and n=5 DAT-KO rats) was 
treated with DNase to avoid DNA contamination. RNA was analyzed by a TaqMan qRT-PCR 
instrument (CFX384 real-time system, Bio-Rad Laboratories) using the iScriptTM one-step RT-
PCR kit for probes (Bio-Rad Laboratories). Samples were run in 384-well formats in triplicate as 
multiplexed reactions. Data were analyzed with the comparative threshold cycle (ΔΔCt) method 
using 36B4 as reference gene. The primer efficiencies were experimentally set up for each couple of 
primers. 
Probes and primers for total BDNF, Creb, CaRF, Npas4 and 36B4 were purchased from Eurofins 
MWG-Operon (Ebersberg, Germany) and their sequences are shown below: 
- total BDNF: forward primer 5’-AAGTCTGCATTACATTCCTCGA-3’, reverse primer 5’ 
GTTTTCTGAAAGAGGGACAGTTTAT-3’, probe 5’-TGTGGTTTGTTGCCGTTGCCAAG-3’; 
- Creb: forward primer 5’-AGATTCTAGTGCCCAGCAAC-3’, reverse primer 5’-
CTGTGCGAATCTGGTATGTTTG-3’, probe 5’-TGTTCAAGCTGCCTCTGGTGATGT-3’; 
- Npas4: forward primer 5’-TCATTGACCCTGCTGACCAT-3’, reverse primer 5’-
AAGCACCAGTTTGTTGCCTG-3’, probe 5’-TGATCGCCTTTTCCGTTGTC-3’; 
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- CaRF: forward primer 5’-GAGATGCACACACCATTCCA-3’, reverse primer 5’-
GTGTTGGCTCATTGGGTTCT-3’, probe 5’-CAGCCATCCAGCTCTTGTTGAAGA-3’; 
- 36B4: forward primer 5’-TTCCCACTGGCTGAAAAGGT-3’, reverse primer 5’-
CGCAGCCGCAAATGC-3’, probe 5’-AAGGCCTTCCTGGCCGATCCATC-3’. 
Probes and primers for BDNF exon IV and BDNF exon VI were purchased from Life Technologies 
(Milan, Italy) (BDNF exon IV: ID Rn01484927_m1 and BDNF exon VI: ID Rn01484928_m1). 
Thermal cycling was started with 10-min incubation at 50 °C (RNA retrotranscription) then 5 min 
at 95 °C (TaqMan polymerase activation). After this, 39 PCR cycles were run. Each PCR cycle 
consisted of heating the samples at 95 °C for 10 s to enable the melting process, then for 30 s at 
60 °C for the annealing and extension reaction. 
 
Protein extraction and western blotting  
Protein extraction and preparation of samples for Western blot analysis were performed as 
described (Vecchio et al, 2017). Briefly, the tissues were dissected from freshly harvested brains. 
Brain samples were mechanically homogenized in RIPA buffer (50 mmol/l Tris–HCl, pH 7.4/150 
mmol/l NaCl/1% Nonidet P-40/0.5% sodium deoxycholate/0.1% SDS; Sigma) plus protease 
inhibitor mixture (Roche 1873580), and protein concentration was measured using a BCA protein 
assay kit (Thermo Scientific). Protein extracts (25 µg) were separated by 10% SDS/PAGE and 
transferred to nitrocellulose membranes (GE Healthcare, Milan, Italy). Blots were immunostained 
overnight at 4°C with the following primary antibodies: Gapdh (FL-335): sc-25778, Santa Cruz 
Biotechnology, Inc., Heidelberg, Germany); DAT (C-20): sc-1433, Santa Cruz Biotechnology, Inc., 
Heidelberg, Germany). After washing, the membranes were incubated for 2 hours at room 
temperature with the appropriate secondary antibody (anti-mouse, anti-rabbit or anti-rat). Following 
secondary antibody incubations, membranes were washed and finally incubated with ECL detection 
reagent (Amersham RPN2232) for 5 minutes. 
For BDNF analysis, medial prefrontal cortex (PFC)	was dissected from a 2-mm section extending 
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from approximately bregma +5.16 to +3.24 (Paxinos and Watson, 2005) and dorsolateral striatum 
(DLStr)	was dissected from a 2-mm section immediately caudal to the PFC section from n=5 WT 
and n=5 DAT-KO rats. Brain areas were immediately frozen on dry ice and stored at -80°C until 
being processed for molecular analysis. Protein extraction was performed as previously described 
(Caffino et al., 2017) with minor modifications. Briefly, PFC and DLStr were homogenized in a 
Teflon-glass potter in cold 0.32 M sucrose buffer pH 7.4 containing 1 mM HEPES, 0.1 mM EGTA 
and 0.1 mM PMSF, in presence of commercial cocktails of protease (Roche, Monza, Italy) and 
phosphatase (Sigma-Aldrich, Milan, Italy) inhibitors and then sonicated. The homogenate of DLStr 
was centrifuged at 800g for 5 min, the obtained supernatant was centrifuged at 13,000 g for 15 min 
obtaining a pellet (P2) and a supernatant (S2), referred as the cytosolic fraction. P2 pellet was 
resuspended in buffer containing 150 mM KCl and 1% Triton X-100 and centrifuged at 100,000 x g 
for 1 h. The resulting supernatant, referred as Triton X-100 soluble fraction (TSF), was stored at -
20°C; the pellet, referred as PSD or Triton X-100 insoluble fraction (TIF), was homogenized in a 
glass–glass potter in 20 mM HEPES, protease and phosphatase inhibitors and stored at -20°C in 
presence of 30% glycerol. Total protein content was measured according to the Bradford Protein 
Assay procedure (Bio-Rad, Milan, Italy) using bovine serum albumin as calibration standard. Equal 
amounts of protein were run under reducing conditions on the criterion TGX precast gels (Bio-Rad 
Laboratories, Milan, Italy) and then electrophoretically transferred onto nitrocellulose membranes 
(Bio-Rad, Milan, Italy). Blots were blocked one hour at room temperature with 10% non-fat dry 
milk in TBS + 0.1% Tween-20 buffer, incubated with antibodies against the phosphorylated forms 
of the proteins and then stripped and reprobed with the antibodies against corresponding total 
proteins. The conditions of the primary antibodies were the following: mBDNF (1:1000, Icosagen, 
San Francisco CA, USA); anti phospho trkB Y706 (1:1000, Santa Cruz Biotechnology, Santa Cruz, 
CA, USA); anti total trkB (1:750, Santa Cruz Biotechnology); anti phospho CaMKII T286 (1:2000, 
Thermo Scientific, Waltham, MA, USA); anti total CaMKII (1:5000, Chemicon, Temecula, CA, 
USA); anti total PSD95 (1:4000, Cell Signaling Technology) and anti β-Actin (1:10000, Sigma-
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Aldrich, Milano, Italy). Results were standardized using β-actin as the control protein, which was 
detected by evaluating the band density at 43 kDa. Immunocomplexes were visualized by 
chemiluminescence using the Chemidoc MP Imaging System (Bio-Rad Laboratories) and analyzed 
using the Image Lab software from Bio-Rad Laboratories. The activation of the proteins 
investigated were expressed as a ratio between the phosphorylated and the respective total forms. 
	
 
In vivo microdialysis 
In vivo brain microdialysis was performed in the right dorsal striatum (DStr) of freely moving rats 
(Carboni et al., 2001; Budygin et al., 2004) using concentric microdialysis probes (2 mm membrane 
length cut off 6000 Da; CMA-11, CMA/Microdialysis, Solna, Sweden). Stereotaxic coordinates for 
the position of the probes were chosen according to the atlas of Franklin and Paxinos (1997) and are 
relative to the bregma: AP 1.0; L 3.0; DV -6.6. Prior to fixation in stereotaxic apparatus, the animals 
were anesthetized with an oxygen/isoflurane mixture. The probes were implanted in the brain 
vertically through a small drilled aperture in the scull and fixed with dental cement. During 
implantation into the brain and for 1 h afterward, the dialysis probes were perfused with artificial 
cerebrospinal fluid (aCSF) (NaCl 147 mM, KCl 2.7 mM, CaCl2 1.2 mM, MgCl2 0.85 mM; CMA 
Microdialysis). 1 h after the operation, the animals were returned to their home cages. 
Approximately 24 h after surgery, the dialysis probes were connected to a syringe pump and 
perfused with the aCSF at 1.0 µl/min for 60 min (equilibration period). To reliably determine the 
basal extracellular DA levels in the striatum of freely moving rats a quantitative “low perfusion” 
rate microdialysis experiment was conducted (Gainetdinov et al., 2003). The perfusate was 
collected at a perfusion rate of 0.1 µl/min every 90 min over a 6 h period into collection tubes 
containing 2 µl of 1 M perchloric acid. To determine effect of AMPH (3 mg/kg, i.p.) on the 
extracellular DA level a “conventional” microdialysis approach was used. Dialysis probes were 
10	
	
connected to a syringe pump and perfused with aCSF at 1 ul/min for at least 60 min for 
equilibration. Then perfusate was collected every 20 min, for 1 hour before injection and 2 hours 
after injection of AMPH. 
 
 
HPLC  
 
HPLC measurements were carried out as described before (Leo et al., 2014). Brain tissues were 
dissected from WT, KO and HET rats and homogenized in 40 volumes of 0.1 M HClO4. Following 
centrifugation and filtration, the samples were analyzed by HPLC as described below. The protocol 
for sample preparation for the HPLC determination of tissue monoamines and their metabolites was 
performed as previously described. Measurements of DA, 5-hydroxytryptamine (5-HT) and 
metabolites in tissue samples and DA in microdialysis samples were performed by HPLC with 
electrochemical detection (ALEXYS LC-EC system, Antec Leyden BV, Netherlands) with a 0.7-
mm glass carbon electrode (Antec; VT-03). The system was equipped with a reverse-phase column 
(3-μm particles, ALB-215 C18, 1x150 mm, Antec) at a flow rate of 200 µl/min. The mobile phase 
contained 50 mM H3PO4, 50 mM citric acid, 8 mM KCl, 0.1 mM EDTA, 400 mg/l octanesulfonic 
acid sodium salt and 10% (vol/vol) methanol, pH 3.9. The sensitivity of this method permitted the 
detection of fmol DA. Dialyzate samples (11 μl) were injected into HPLC without any additional 
purification. 
 
	
 
Fast Scan Cyclic Voltammetry (FSCV) 
 
The brains were sectioned in cold carboxygenated artificial cerebrospinal fluid (aCSF) (126 mM 
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NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 25 mM NaHCO3, 2.4 mM CaCl2, 11 mM D-glucose, 1.2 
mM MgCl2) on a VT1000S vibrating microtome (Leica Microsystems, Nussloch, Germany) at a 
thickness of 300 µm. Coronal slices containing the dorsal striatum were allowed to recover for at 
least 1 h at room temperature in carboxygenated aCSF. For recordings, slices were superfused with 
32 °C carboxygenated aCSF at a flow rate of 1 ml/min. FSCV recordings started 20 min after 
transfer to the slice chamber. Carbon fiber electrodes (7 µm diameter, Goodfellow, Huntingdon, 
England) were made as previously described ( Kawagoe et al, 1993; Kuhr and Wightman, 1986a). 
The carbon fibers were trimmed with a scalpel to 80-120 µm under a microscope (Nikon) A carbon 
fiber microelectrode was inserted into the slice and a twisted bipolar stimulating electrode (Plastics 
One, Roanoke, VA) was placed on the surface of the brain slice ~200 µm away. The potential of the 
working electrode was held at -0.4 V and scanned to +1.3 V and back at 300 V/s. Axonal DA 
release in the striatum was evoked by a single biphasic electrical pulse (1 ms long, 400 µA) every 2 
min through a stimulus isolator (AM-system, Carlsborg, WA). Data were filtered to reduce noise. 
Oxidation and reduction peaks were observed at ~ +0.65 V and -0.2 V (vs. Ag/AgCl reference) 
identifying DA as the released chemical. Electrodes were calibrated in a flow injection system using 
1 µM DA (Sigma Aldrich, St. Louis, MO, USA).	
 
FSCV kinetic analysis 
There were several established criteria for choosing which DA signals to use for analysis, two of 
these being that there should be no confounding electrical artefacts to interfere with the DA traces, 
and no pH shifts during recordings, which allow for a flat baseline before stimulation and provide 
the most uncontaminated DA dynamics as possible, Next, a 10:1 signal to noise ratio was used in 
order to guarantee that the actual signal was separated from background. All of these criteria 
insured accuracy in analysis. One to two recordings from each experimental group were excluded 
from analysis based on these criteria. 
Data analysis was performed using Demon Voltammetry software described (Yorgason et al., 
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2011a). Briefly, computations were based on user-defined positions on current traces for baseline 
(Pre-Stim cursor), peak (Peak Cursor) and return to baseline (Post-Stim cursor) positions. Half-life 
values were determined from exponential fit curves based on Peak cursor and Post-Stim cursor 
positions using a least squares constrained exponential fit algorithm (National Instruments, Milan, 
Italy) (Yorgason et al., 2011a). These measurements were performed on individual traces within 
each experiment. These numbers were then averaged within each experimental group (WT, KO and 
KO treated) and reported as mean ± SEM. (n=4 for WT and KO control; n=6 for KO treated group). 
Half-life is considered to be a reliable measure for evaluating changes in striatal DA clearance in 
vivo and in vitro. This parameter accurately distinguishes differences in clearance rate similar to 
other established measures (Yorgason et al, 2011). 	
 
Locomotor activity in a novel environment 
Locomotor activity was evaluated as described before (Sukhanov et al., 2014) by using an 
automated Omnitech Digiscan apparatus (AccuScan Instruments, USA) under illuminated 
conditions. The apparatus included four open field monitors, each consisting of a set of 16 light 
beams arrayed in the horizontal X and Y axes. The hardware detected beams broken by the animal, 
allowing the software to determine the location of the rat in the cage. Cages were divided into four 
compartments (20 cm x 20 cm). Animals were tested individually for defined periods with 5-min 
intervals. The total distance traveled was measured and expressed in terms of centimeters traveled 
by the animal.	In addition, vertical activity as expressed in terms of the number of beam breaks. All 
rats were habituated to the test room for at least 1 hour prior to testing. Effects of drugs on 
locomotor activity in a novel environment were tested 30 min after placement of animals into 
locomotor activity monitor. d-AMPH hydrochloride, MPH hydrochloride, haloperidol (Sigma–
Aldrich, Co., St. Louis, MO) and RO5203648 (F. Hoffmann-La Roche Ltd., Basel, Switzerland) 
were dissolved as described (Gainetdinov et al, 1999; Spielewoy et al, 2000; Revel et al., 2012).  
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For all behavioral experiments, drugs were administered intraperitoneally (i.p.) in a volume of 1 
ml/kg. All solutions were made fresh daily. 	
 
24-hour spontaneous locomotor activity in a home cage 
Rats were continuously monitored for spontaneous home-cage locomotor activity by means of an 
automatic device equipped with small passive infrared sensors placed on a standard rack over the 
top of each home-cage (ActiviScope system; TechnoSmart, Rome, Italy). These sensors (20 Hz) 
detected any movement of rats: scores were automatically divided into 60-min intervals. 
 
Y maze spontaneous alteration test 
To measure spontaneous alternation behavior and exploratory activity, a white plastic material 
Y-maze with arms 40 cm (long) by 6 cm (wide) with 13 cm walls was used. Each animal was 
tested in a single 8-min session, during which the animal was placed in the central platform and 
allowed free exploration of the maze. Spontaneous alternation, expressed as a percentage, refers 
to ratio of arm choices differing from the previous two choices to the total number of arm 
entries. 
	
 
Startle and PPI test 
Startle and Pre-Pulse Inhibition (PPI) testing were performed as described (Frau et al., 2016). The 
apparatus used for detection of startle reflexes (Med Associates, St Albans, VT, USA) consists of 
four standard cages placed in sound-attenuated chambers with fan ventilation. Each cage consists of 
a Plexiglas cylinder of 9 cm diameter, mounted on a piezoelectric accelerometric platform 
connected to an analogue-digital converter. Two separate speakers convey background noise and 
acoustic bursts. Both speakers and startle cages are connected to a main PC, which detects and 
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analyzes all chamber variables with specific software. Before each testing session, acoustic stimuli 
and mechanical responses were calibrated. 
The test begins with a 5-min acclimatization period, with a 70-dB background white noise, which 
continues for the entire session. The acclimatization period is followed by three blocks, each 
consisting of a sequence of trials: the first and the third block consist of five pulse-alone trials of 
115 dB. The second block consists of a pseudorandom sequence of 50 trials, including 12 pulse-
alone trials, 30 trials of pulse preceded by 74, 78, or 82 dB pre-pulses (10 for each level of pre-pulse 
loudness), and 8 no-pulse trials, where only the background noise is delivered. Inter-trial intervals 
(i.e., the time between two consecutive trials) are randomly selected between 10 and 15 s. The % 
PPI was calculated using the following formula: 100 - (mean startle amplitude for pre-pulse pulse 
trials/ mean startle amplitude for pulse alone trials) x 100.  
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Results 
Generation of DAT-KO rats 
Slc6a3 (DAT) KO rats were generated by Sigma Advanced Genetic Engineering Labs (SAGE® 
Labs; Sigma–Aldrich Co., St. Louis, MO). DAT-KO rats were created by using ZFN technology 
that produces a 5 bp mutation and an early stop codon (Fig. 1A). The targeted DNA to be deleted 
(Slc6a3 exon 2) contained a specific nucleotide sequence substrate for restriction enzyme BtsIMutI. 
According to our genetically modified model, disruption of this specific sequence causes the loss of 
restriction site for BtsIMutI enzyme, resulting in wild-type rats (WT) maintaining all restriction 
sites on both alleles while heterozygous (DAT-HET) rats bear one truncated allele and an intact 
one. DAT-KO rats lose both restriction enzyme sites as predicted. (Fig. 1B). PCR primers were 
designed according to protocol and amplified DNA was digested as shown (Fig. 1B and C). In 
DAT-KO rats no detection of digestion product was observed, due to the loss of restriction site on 
both alleles. DAT-HET rats show both the digested DNA at lower molecular weight and mutated 
DNA, while WT DNA amplicon was completely digested by BtsIMutI, thus resulting in one single 
band at lower molecular weight (Fig. 1B and C). We also verified the absence of DAT protein in 
KO animals in western blot from striatal tissue (Fig. 1D).  
While there are reasonable concerns for potential off-targeting effects of gene editing nucleases 
(including ZFN) technologies, there are little chances for these events in DAT-KO rats. First, 
the ZFN designs were generated using a proprietary algorithm by bioinformatics team at SAGE 
Laboratories that screens each design for the top 20 most homologous sequences, as well as for 
repeat elements, SNPs, and splice variants. In addition, used ZFN contains specifically engineered 
obligate heterodimer FokI cleavage domains that help guard against off-targeting by increasing 
specificity to cut at only the desired site. In any case, founder animals were breed back to WT 
Wistar Han rats (Charles River, France) for 6 generations that should be sufficient to cross away 
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any potential unintended off-target effects that may have occurred even with rigorous screening in 
the ZFN design and construction phase.  
 
 
Wistar Han DAT-KO rat colony was kept under HET-HET breeding.	Surprisingly, DAT-KO rats 
do not show a propensity to premature death as DAT-KO mice (Giros et al., 1996). They are viable 
as the WT controls (followed up to 5 months) and the colony follows the expected Mendelian ratio 
at age 4 months (1:2:1; Fig. 1E). Analysis of body weight from birth up to adulthood (4 months) 
reveled a major effect of genotype in both male and female populations (Fig. 1F) with DAT-KO 
animals showing lower weights compared to HET and WT siblings (Fig. 1F).	
 
Neurochemical characterization of striatal DA transmission in DAT-KO rats 
  
Analysis of DA dynamics by Fast Scan Cyclic Voltammetry 
In order to evaluate consequences of DAT gene deletion on the extracellular dynamics of DA we 
employed Fast Scan Cyclic Voltammetry (FSCV) technique on brain slices (Jones et al., 1998). 
First, we detected the kinetics of evoked DA release and clearance following single pulse (400 µA, 
1 ms, biphasic) stimulation in DStr slices prepared from DAT-KO, DAT-HET and WT littermates. 
The oxidation peak occurred at approximately +0.6 V and the reduction peak at approximately -0.2 
V (Fig. 2A, insert), consistent with the electrochemical characteristics of DA 	(Bradaia	et	al.,	2009;	
Leo	et	al.,	2014)(Jones	et	al.,	2006;	John	and	Jones,	2007). The maximal amplitude of DA overflow 
evoked by single pulses in the DStr was not significantly different between genotypes but the 
clearance of released DA was markedly prolonged in DAT-HET and DAT-KO rats (Fig. 2A, B, C). 
We evaluated the uptake kinetics from an exponential fit curve using a least squares-constrained 
exponential fit algorithm (Yorgason et al., 2011) and quantified the half-life parameters for an 
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estimation of DA uptake rates. Under basal conditions, the time to clear released DA was 1.3, 10 
and 50 seconds respectively in WT, DAT-HET and DAT-KO rats (Fig. 2B).  
Next, we evaluated the effect of cocaine on evoked DA release and clearance. As might be 
expected, application of 3 µM cocaine progressively prolonged an amplitude of striatal DA outflow 
and clearance (John and Jones, 2007) in WT and DAT-HET, but not in DAT-KO rats (Fig. 2C, D). 
Further, in order to test whether serotonin transporter (SERT) could provide extracellular DA 
clearance via promiscuous uptake, we applied 10 µM fluoxetine, a selective SERT blocker. As 
presented (Fig. 2E), fluoxetine did not affect DA clearance in any of the genotypes. To evaluate if 
DA metabolizing enzymes can contribute to the clearance of DA in the absence of DAT we then 
tested the effect of the inhibition of Catechol-O-methyl-transferase (COMT) by 10 µM tolcapone 
(Fig. 2F) and monoamine oxidase (MAO) by 10 µM pargyline (Fig. 2G). COMT inhibition did not 
alter the kinetics of DA clearance in any genotype whereas inhibition of MAO did not affect 
released DA half-life in WT or DAT-HET animals but prolonged it in DAT-KO rats (Fig. 2F, G). 
 
Analysis of extracellular DA levels by in vivo microdialysis 
To evaluate the consequences of disrupted DA clearance on the basal extracellular DA levels, we 
applied a quantitative low perfusion rate microdialysis approach to freely moving animals that, 
unlike conventional microdialysis, provides a true measure of extracellular neurotransmitter 
concentrations (Bradaia et al., 2009; Leo et al., 2014). As expected, DAT-KO and DAT-HET rats 
showed an increased amount of basal extracellular DA levels in the striatum with about	8-fold and 
3-fold increase over WT levels, respectively (Fig. 3A).  Levels of DA metabolites DOPAC and 
HVA were elevated in DAT-KO rats only.  Furthermore, to assess effects of AMPH on striatal DA 
release, we administered AMPH and monitored the extracellular levels of DA in the striatum of 
freely moving rats by a conventional microdialysis. As expected, AMPH produced a genotype-
dependent effect (Fig. 3D, E, F). AMPH induced significant increase in extracellular DA in WT and 
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to a lesser degree in DAT-HET rats. At the same time, no effect was found in animals lacking the 
DAT.	
 
Striatal tissue DA and metabolites 
We next evaluated the total tissue content of monoamines and their metabolites in the striatum (Fig. 
3G). Like in DAT-KO mice (Jones et al., 1998), we observed a pronounced reduction in total tissue 
DA levels in DAT-KO rats (around 13 fold; Fig. 3G) compared to control and HET animals. At the 
same time, the levels an intraneuronal DA metabolite DOPAC and predominantly extracellular DA 
metabolite HVA, appeared to be significantly increased in DAT-KO rats.  
Expression profile of selected DA-related genes in striatal samples 
To evaluate the consequences of remarkable changes in the extracellular DA due to absence of re-
uptake process, we evaluated by real time PCR the expression of genes critical for DA homeostasis. 
In the striatum, DAT-KO animals showed an increased TH mRNA expression (Fig. 3H), but 
decreased levels of both dopamine D1 (D1R) and dopamine D2 (D2R) receptors (Fig. 3I and J, 
respectively). 
 
Behavioral Phenotyping of DAT-KO rats 
 
Locomotor activity tests 
It is well known, that alterations in DAT function cause pronounced changes in locomotor behavior 
by influencing the dopaminergic tone in the basal ganglia (Giros et al., 1996). We evaluated the 
locomotor activity of mutant rats in home cages during 24 hours and observed a significantly 
altered pattern of motor activity in DAT-KO animals that varied according to the light/dark cycle, 
increasing significantly during the night compared to WT and HET siblings (Fig. 4A). Locomotor 
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activity of DAT rats was also assessed in a novel environment in illuminated conditions using 
activity chambers. Total distance traveled and vertical locomotor activity counts were recorded in 
1.5, 2.0, 2.5, 3.0 and 4.0 months-old animals (Fig. 4B, C). In each tested age, total distance traveled 
by DAT-KO rats was highly elevated comparing WT and DAT-HET animals, with a characteristic 
to DAT-KO mice perseverative locomotor pattern of activity (Ralph et al., 2001). DAT-KO rats 
also displayed prominent vertical activity at all tested ages (Fig. 4D, E). 	
Next, we evaluated effects of compounds that are known to suppress hyperactivity of DAT-KO 
mice (Gainetdinov, 2008). Among them, the most noticeable are psychostimulants AMPH and 
MPH used in the treatment of ADHD (Gainetdinov et al., 1999). Administration of AMPH (1, 2, 3, 
and 4 mg/kg i.p.) to DAT-KO animals had a paradoxical calming effect in hyperactive DAT-KO 
animals with the most significant effect starting from 2 mg/kg AMPH (Fig. 4F and G). In WT and 
HET rats, treatment with this psychostimulant produced a significant increase in locomotor activity 
(Fig. 4F and G). Similar results were obtained with MPH (Ritalin ®) drug of choice in the treatment 
of ADHD. Administration of 1.5, 2.5 and 5 mg/kg MPH dose-dependently reduced the 
hyperlocomotion in DAT-KO animals (Fig. 4F and G) while inducing a strong increase in WT and 
DAT-HET rats. Recent studies have revealed that Trace Amine-Associated Receptor 1 (TAAR1) 
can regulate the DA system and affect dopamine-related behaviors. As it has been shown previously 
in DAT-KO mice (Revel et al., 2011), the partial TAAR1 agonist, RO5203648, effectively reduced 
the hyperlocomotor behavior of DAT-KO rats without significant effect in control and DAT-HET 
animals (Fig. 4F and G). We finally demonstrated that the administration of the typical 
antipsychotic drug, haloperidol (0.5 mg/kg, s.c.), potently reversed hyperlocomotion in the DAT 
mutant rat model as it does in DAT-KO mice (Gainetdinov et al., 1999). Haloperidol administration 
also reduced the locomotor activity of WT and DAT-HET rats (Fig. 4F and G)	
 
Cognitive tests 
20	
	
To evaluate the consequences of DAT-deficiency related hyperdopaminergia on cognitive abilities 
of rats we first employed Y-maze task. The performance of the rats in the Y-maze task is expressed 
as a percentage and refers to ratio of arm choices differing from the previous two choices to the 
total number of arm entries. DAT-KO rats alternated between the arms of the maze significantly 
less than control indicating deficiency in working memory (Fig. 5A). Importantly, analysis of food 
consumption (ad libitum) revealed no difference in food intake between genotypes (data not 
shown).	Finally, KO rats showed significant difference also in the startle response and pre-pulse 
inhibition test, used to assess sensorimotor gating functioning (Fig. 7B and C). DAT-KO rats 
showed an increased startle response amplitude and impaired pre-pulse inhibition compared to WT 
and DAT-HET rats. Two-way ANOVAs revealed significant differences both in startle response [F 
(2,42) = 7.35, P < 0.01] and pre-pulse inhibition [F (2,42) = 21.11, P < 0.001] (for significance level 
of single points see Fig. 7B and C). No differences were found between WT and DAT-HET rats (all 
P > 0.05). 	
 
Analysis of BDNF transmission in DAT-KO rats 
In an attempt to investigate the putative mechanisms responsible for the cognitive impairment in 
DAT-KO rats, we evaluated the pattern of BDNF expression in the rat prefrontal cortex. Fig. XX 
shows that, in the homogenate, total BDNF mRNA levels are reduced in the prefrontal cortex of 
DAT-KO rats. In order to get further insights into the complex organization of the BDNF gene, we 
investigated the modulation of several transcripts whose expression is driven by separate promoters 
(Aid et al. 2007). We focused our analysis on BDNF exon IV, the most abundant transcript whose 
transcription is activity-dependent, and exon VI, primarily targeted to dendrites (Pruunsild et al., 
2011). Interestingly, the analysis of these different BDNF transcripts revealed that such decrease 
could be ascribed to BDNF exon IV since no changes were seen in BDNF exon VI (Fig. 5 XXX). 
We then restricted our analysis to the regulation of promoter responsible for the transcription of 
BDNF exon IV, by investigating its main transcription factors. We found reduced gene expression 
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of the calcium responsive factor (CaRF) and neuronal Per-Arnt-Sim domain protein 4 (Npas4) with 
no changes in cAMP responsive element binding protein (Creb). Since the reduction of CaRF 
mRNA levels may suggest defective processes mediating calcium influx, we measured the 
Ca2+/calmodulin-dependent protein kinase II (aCaMKII), known to be activated by calcium. As 
shown in fig. 5XY, the activation of aCaMKII is significantly reduced in the prefrontal cortex of 
DAT KO rats. We then measured BDNF protein levels in the prefrontal cortex and found it reduced 
(Fig. 5xxyy). Similarly, we found a significant reduction in the activation of the high affinity BDNF 
receptor trkB. 
We then measured mBDNF expression and signaling in rat dorsolateral striatum. Fig. 5X shows 
that lack of DAT induces the subcellular redistribution of the neurotrophin in this brain region, as 
mBDNF is increased in the cytosol of dorsolateral striatum while reduced in the post-synaptic 
density. Additionally, in the post-synaptic density of the dorsolateral striatum, we found reduced 
expression and phosphorylation of the high affinity BDNF receptor, trkB (Fig. 5x) suggesting a 
reduced BDNF-mediated signaling in DAT-KO rats. As the interaction between dopaminergic and 
glutamatergic systems in the striatum are important for cognitive processing, we examined the 
expression of a critical determinant of glutamate transmission, PSD-95, as an index of glutamate 
spine density, and found a reduced expression of PSD-95 in the striatum of DAT-KO rats compared 
to WT counterparts (Fig. 5G). 
 
 
Discussion 
The involvement of DA neurotransmission in several physiological and pathological conditions has 
led to intense studies on animal models of dopaminergic dysfunction. One such model, DAT-KO 
mice, has provided numerous advances in understanding the role of DA in these disorders (Giros et 
al., 1996; Gainetdinov, 2008). Here we describe the rat KO model of DAT deficiency that provides 
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certain advantages compared to the mouse model. Rat models offer many powerful advantages: the 
larger size means larger tissues and samples that can lead to a reduction in the number of animals 
required for a study. Moreover, the larger size of the rat allows surgeries that are much easier to 
perform, particularly in small brain areas. Rats are particularly far superior in comparison to mice 
when it comes to behavioural assays. They perform much more reliably and robustly than mice, and 
mouse behavioural assays typically require larger cohort sizes than those needed for rats due to 
increased variability. In the end, an animal model must be representative of human physiology 
and/or disease. The rat is inherently more translational than a mouse with closer physiology, richer 
behaviour, more robust and reproducible assay performance. 	
DAT-KO rats are viable and demonstrate the expected Mendelian ratio at 4 months of age. By 
comparison, DAT-KO mice showed a continuous decrease in survival rate starting from 4 weeks of 
age with about 35% of mutants demonstrating neurological dysfunctions and death due to 
postsynaptic neurodegeneration (Cyr et al., 2003). Like mutant mice, DAT-KO rats develop 
normally but weigh less than HET and WT control animals, an effect independent from food intake 
(Bossé et al., 1997). 	
To evaluate the neurochemical consequences of the absence of DAT on striatal DA transmission, 
we first measured real time extracellular DA dynamics following evoked release by using FSCV. 
As in DAT-KO mice (Jones et al., 1998), DA persists for a protracted period in the synaptic cleft in 
DAT-HET and DAT-KO rats. The clearance of extracellular DA was about 40-fold slower in the 
striatum of DAT-KO compared to WT controls while decreased about 2-fold in DAT-HET rats. 
Extracellular half-life of evoked DA in the striatal slices of DAT-KO animals was not altered by 
cocaine, fluoxetine or COMT inhibitor tolcapone. At the same time it was somewhat prolonged by 
MAO inhibitor pargyline, indicating that while diffusion is the major mechanism available to 
eliminate DA from the extracellular space in the absence of DAT (Jones et al., 1998), there is some 
minor contribution of MAO in DA clearance as well (Benoit-Marand et al., 2000). As in DAT-KO 
mice (Jones et al., 1998), prolonged extracellular lifetime of released DA resulted in about 3 and 7-
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fold increase in striatal basal extracellular levels of DA in DAT-HET and DAT-KO rats, 
respectively. At the same time, total tissue content of striatal DA was reduced 13-fold, indicating 
the critical contribution of DAT-mediated transport of DA in maintenance of intraneuronal stores of 
DA (Jones et al., 1998). The only difference with DAT-KO mice was a significant increase in total 
tissue concentration of DOPAC, presumably indicating a more prominent role of MAO in 
metabolism of DA in rats. As for cocaine in FSCV experiments, AMPH effects on striatal 
extracellular DA levels was absent in DAT-KO and reduced in DAT-HET rats, indicating the 
critical role of DAT in the effects of this psychostimulant. The absence of DAT and the persistent 
elevation of DA in the synaptic cleft produce profound variation in key DA-related genes. Like in 
DAT-KO mice (Giros et al., 1996) striatal mRNA levels of the two major DA receptors, D1 (D1R) 
and D2 (D2R) are significantly decreased. At the same time, striatal mRNA levels of the rate-
limiting enzyme for DA biosynthesis, TH was increased in DAT-KO rats, while a small decrease 
was observed in DAT-deficient mice (Jaber et al., 1999).  	
 
The most prominent phenotype of DAT-KO rats is the hyperlocomotion determined by an increased 
DA tone in basal ganglia. DAT-KO rats showed an intense locomotor activity both in a new 
environment and in the home cages. The hyperlocomotion of homozygous KO rats persists during 
the lifespan, and as already seen in DAT-KO mice, is greater than the effect produced by DAT 
blocker drugs (Giros et al., 1996). As in DAT-KO mice, AMPH and MPH significantly reduced 
locomotor activity of DAT-KO rats while inducing the well-known increase in DAT-HET and WT 
animals (Gainetdinov et al., 1999). The psychostimulatory actions of AMPH and MPH are 
primarily dependent on a direct interaction of these compounds with DAT, leading to elevated DA 
(Fumagalli et al., 1998; Chen et al., 2006; Thomsen et al., 2009). Because DAT-KO rats lack the 
major target of AMPH action, the “calming” effect of psychostimulants suggests the involvement of 
a DAT-independent mechanism of action, possibly involving other monoamine transporters. 
Interestingly, we observed an inhibitory action of MPH at lower (about 10-fold) doses in rats in 
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comparison to mice (Gainetdinov et al., 1999) suggesting significant differences in 
pharmacodynamic or pharmacokinetic properties of this drug between these species. Hyperactivity 
and paradoxical inhibitory effects of psychostimulants used in the treatment of ADHD, could be a 
first indication of face and predictive validity of DAT-KO rats as an improved animal model for this 
disorder. Moreover, the ability of the partial TAAR1 agonist, RO5203648, to modulate the 
locomotor behaviour of DAT-KO rats supports the potential of TAAR1 as a target for therapeutic 
intervention in DA-related disorders. Previous data showed that activation of TAAR1 strongly 
regulates DA transmission and reduces DA-dependent behavioural effects of psychostimulants as 
well as hyperactivity of DAT-KO mice (Bradaia et al., 2009; Leo et al., 2014) likely via an 
interaction of TAAR1 with D2R or with different neurotransmitter pathways, such as the 
glutamatergic (Espinoza et al., 2015). 	
As an indication of DA-related cognitive deficits, DAT-KO rats, like DAT-KO mice, show an 
impaired sensorimotor gating measured as reduced pre-pulse inhibition (PPI) of the acoustic startle 
reflex (Ralph et al., 2001). Notably, DA hyperactivation, induced by pharmacological interventions 
or genetic manipulation of DAT, causes PPI deficits in experimental animals similar to those 
observed in psychiatric disorders, such as schizophrenia and ADHD (Braff et al., 2001; Swerdlow 
et al., 2001); (Yamashita et al., 2006; Arime et al., 2012). DAT-KO rats show also a decreased Y-
maze spontaneous alternation that indicated an impaired working memory function. Since intact 
dopaminergic signalling in the prefrontal cortex seems to be required for correct mnemonic function 
(Goldman-Rakic, 1996; Kesner and Rogers, 2004), we can postulate that absence of DA reuptake 
could impair the retention of short term memory information in DAT-KO rats. At least some of 
these dopaminergic effects may involve D1 receptors (Lidow et al., 1991; Goldman-Rakic et al., 
1992; Gaspar et al., 1995).  
In an attempt to find a molecular correlate of the above shown cognitive deficit, we focused 
our attention on the neurotrophin BDNF, which plays a role in working memory (Egan et al, 2003) 
and whose expression was found to be developmentally dysregulated in the prefrontal cortex of 
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DAT-KO mice (Fumagalli et al, 2003). We found that DAT deletion in rats reduces total BDNF 
mRNA levels in the prefrontal cortex. Further, the analysis of the main different transcripts 
produced by the activation of the different promoters at 5’-UTR revealed that only BDNF exon IV 
is reduced. Since this transcript is tightly dependent on neuronal activity we suggest that, in these 
rats, activity-dependent gene expression is impaired. Moreover, the analysis of the transcription 
factors involved in the modulation of BDNF exon IV showed that the expression of the neuronal 
transcription factor NPAS 4, an immediate early gene selectively induced by neuronal activity (Sun 
and Lin, 2016), is reduced as well. Notably, the expression of calcium responsive factor CaRF, 
which also regulates the BDNF exon IV expression, is reduced suggesting reduced calcium influx, 
an evidence corroborated by the reduced activation of aCaMKII, a well-known intracellular 
calcium sensor required for CaRF activity (Zheng et al., 2011). Given that both calcium influx and 
aCaMKII activation often represent the first stimulus for activity-dependent gene expression in 
neurons (Fields et al., 2005), we suggest defective calcium influx as a potential mechanism for the 
impairment in the cortical activity-dependent gene expression in the prefrontal cortex of DAT KO 
rats. 
Changes in BDNF mRNA levels were accompanied by a down-regulation of BDNF protein levels, 
suggesting that DAT deletion regulates also the translation of the neurotrophin. Of note, we also 
found reduced activation of the high affinity BDNF receptor trkB, suggesting that, in the prefrontal 
cortex of DAT KO rats, the BDNF-mediated transmission is impaired, an effect that may contribute 
to the impaired working memory function (Galloway et al., 2008). 
Our analyses also revealed that the removal of DAT altered the BDNF system also in the 
dorsolateral striatum, where it results in a redistribution of the neurotrophin. In the whole 
homogenate, we found increased expression of BDNF leading to the activation of trkB and its 
downstream intracellular signalling; however, the removal of DAT has led to increased BDNF 
expression in the cytosol while reducing its expression, together with its downstream signalling, in 
the post-synaptic density. This observation may have a relevant and functional effect, given the 
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well-established role of BDNF in the control of glutamatergic spine density (Young et al, 2015) and 
since reduced spine density was reported in striatal medium spiny neurons of DAT-KO mice 
(Berlanga et al, 2011).  In fact, in line with the herein shown reduced BDNF expression, we also 
found a decreased expression of the marker of glutamatergic spines PSD-95, as previously observed 
in DAT-KO mice (Yao et al, 2004), suggesting potential structural rearrangements of glutamate 
neurons in the dorsolateral striatum. 
Taken together, these observations indicate that DAT-KO rats represent an improved model of 
persistently increased dopaminergic transmission, that is presumably involved, at least in part, in 
endophenotypes of such disorders as schizophrenia, bipolar disorder, ADHD and Huntington’s 
disease (Carlsson, 1987; Howes and Kapur, 2009; Gardoni and Bellone, 2015; Bonvicini et al., 
2016). These rats have obvious advantages over mouse models by having increased survival rate, a 
larger size of the brain allowing investigations of smaller brain regions and being closer 
physiologically to humans. Since behavioural repertoire of rats is significantly more complex in 
comparison to mice, mutant rats could be particularly useful to evaluate the effects of novel 
therapeutics on cognitive functions.	
 
 
Figure Legends 
Figure 1. Generation of DAT knockout (KO) rats. A) DAT KO rats were generated by using zinc 
finger nuclease (ZFN) technology that produces a 5 bp deletion and an early stop codon. Green 
solid lines indicate exons 2 and 3, grey solid lines indicate introns; yellow boxes indicate DNA 
domains interaction sites; blue box indicates KO targeting site; red box indicate early stop codon 
generated after frameshift due to cleavage of 5 base pairs operated by ZFN. B and C) PCR primers 
were designed (black arrows). Wildtype (WT) DNA contains BtsIMutI restriction enzyme site (blue 
brackets). WT amplified DNA is fully digested into two low molecular weight bands (104 bp and 
71 bp). Homozygote mutated DNA loses digestion sites on both alleles, therefore resulting in only 
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one final PCR product of 170 bp. Heterozygosis shows both digested DNA at lower molecular 
weight from the WT allele and mutated DNA at 170 bp. D) Western Blot analysis on striatal 
samples of DAT rats. DAT-KO rats show complete absence of DAT protein, whereas HET and WT 
still have DAT protein expression. E) Rats were bred following heterozygous (HET) male/HET 
female breeding scheme. 223 animals were born from 19 offsprings and we obtained 62 DAT+/+ 
(26.46%), 102 DAT+/- (45.74%) and 59 DAT-/- (27.80%), numbers very close to the ratio (1:2:1) 
expected in the absence of pre- and postnatal death. Infantile mortality is completely absent for all 
three genotypes up to 4 months. Population genotype distribution was analyzed by Chi-square test 
(Chi-square=1,7; DF=2; p=0,4275), showing that discrepancy of obtained data is not significant 
different from expected Mendelian distribution 1:2:1, resulting from mating of HET. F) 
Developmental phenotype. Both DAT-KO rats male and female develop normally but have lower 
weight in comparison to HET and WT rats. 
 
Figure 2. Recording of electrically stimulated DA efflux in striatal brain slices from DAT rats. A) 
A single biphasic stimulus (400 µA, 1 ms) was used to evoke DA release in striatal brain slices 
from WT, HET and KO rats. The average time to clear released DA is 1.3, 10 and 50 seconds, 
respectively. Lower panel: Color plots represent the voltammetric currents (encoded in color in the 
z axis) plotted against the applied potential (y axis) and time (x axis). Upper Panel: Cyclic 
voltammogram identifies the detected analyte as DA. B) Kinetics of evoked DA release in dorsal 
striatum of DAT-WT, HET and KO. C and D) Effect of 3 µM cocaine on evoked DA release. 
Cocaine had no effect on evoked DA overflow in DAT-KO rats but induced the well know increase 
in DA release in both WT and HET (C) Cocaine-induces changes in half-life (D). E) 10µM of 
Fluoxetine effect on half-life of evoked DA release. F) 10 µM of Tolcapone effect on effect on half-
life of evoked DA release. G) Pargyline effect on effect on half-life of evoked DA release. 
Inhibition of MAOs by 10 µM pargyline. 
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Figure 3. A-C) Quantitative low perfusion rate microdialysis showed an increased amount of 
released DA (A) in DAT-KO striata about 8-fold control values followed by a marked increase in 
both DA metabolites, DOPAC (B) and HVA (C). Results are the mean ± SEM of six independent 
experiments. E-F) Effect of AMPH (3 mg/kg, i.p.) on extracellular DA measured by microdialysis 
in the striatum of freely moving rats. Results are the mean ± SEM of six independent experiments. 
G) Neurochemical phenotype of DAT-KO rats. HPLC analysis on striatal samples showed 13-fold 
decrease in DA level along with increased metabolites (DOPAC and HVA). H-J) Molecular profile 
of selected DA related genes in striatal samples. H) TH mRNA expression is increased selectively 
in DAT-KO striatal samples (WT vs KO p= 0.0004 and HET vs KO p=0.0019, n=6; one-way 
ANOVA) I) D1R mRNA are decreased in both HET and KO striatal samples. (WT vs HET p= 
0.0056 and WT vs KO p=0.0004; HET vs KO, p=0.0489, n=6; one-way ANOVA. J) D2R mRNA 
expression is reduced only in DAT-KO striatal samples (WT vs KO p=0.0039, HET vs KO, 
p=0.0018, n=6; one-way ANOVA.). 
 
Figure 4. Basal locomotor activity of DAT-KO rats. A) Locomotor activity of adult animals was 
recorded in home cages for 24 hours. B-D) Traveled total distance and vertical activity of animals at 
different ages were assessed using an automated Omnitech Digiscan open fields for 2 hours. C-E) 
Additionally, total distance and vertical activity of 4 month-old animals were evaluated for 4 hours 
in the automated open fields. The results are expressed as the mean ± SEM. * and # P < 0.001 
(Bonferroni’s test), relative to the corresponding WT (*) or HT (#) control groups. N = 6–20 per 
group. F-G) Drug effects on locomotor activity of DAT-KO rats. Before drug administration, the 
mice were habituated to the activity monitor for 30 min. After drug injection, the locomotor activity 
of the animals was recorded for additional 70 min. Total distance covered (F) and the vertical 
activity (G) for the 60 min period (from 40 min to 100 min) were used for subsequent analysis. The 
results are expressed as the mean ± SEM. * P < 0.05 (Dunnet’s test, t-test), relative to the 
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corresponding saline-treated control group. N = 6–19 per group, with exception of DAT-HET rats 
treated with haloperidol (n=4). 
 
Figure 5. A) Spontaneous alternation test. To measure spontaneous alternation behavior and 
exploratory activity, a white plastic material Y-maze with arms 40 cm (long) by 6 cm (wide) with 
13 cm walls was used. Each animal was tested in a single 8-min session, during the course of which 
the animal was placed in the central platform and allowed free exploration of the maze. 
Spontaneous alternation, expressed as a percentage, refers to ratio of arm choices differing from the 
previous two choices to the total number of arm entries. The percentage of alternation observed is 
strongly reduced in KO animals. Values are expressed as Mean ± SEM of 8 rats/group. *P < 0.05, 
with respect to WT and HET rats B) Startle response and C) Pre-pulse inhibition of the startle 
response. The day of the test, rats were transferred in the experimental room under environmentally 
controlled conditions (sound proof and red dim lights) and after 30 min of habituation were 
positioned in the apparatus and startle response and pre-pulse inhibition assessed (see methods 
section). Rats were tested one once. Values are expressed as Mean ± SEM of 8 rats/group. Block1, 
Block2 and Block3 indicate the three consecutive sequences of stimuli of the test. PP1, PP2 and 
PP3 indicate the three different intensities of the pre-pulse stimulus. Two-way ANOVA followed by 
Bonferroni’s pair wise contrasts. *P < 0.05, **P < 0.01, ***P < 0.001 with respect to WT rats. D-
G) Analysis of BDNF transmission in DAT-KO rats. X) Total BDNF (-12%, t(8)= 3.2; p= 0.013) 
and BDNF exon IV (-20%, t(8)= 4.43; p= 0.002) mRNA levels are reduced in the prefrontal cortex 
(PFC) of DAT-KO rats, while no changes were observed in the levels of BDNF exon VI (+2%, t(8)= 
0.26; p= 0.80). X) The analysis of the transcription factors involved in the modulation of BDNF 
exon IV revealed a significant reduction in the expression of Npas4 (-40%, t(8)= 5.41; p= 0.0006) 
and CaRF (-21%, t(8)= 4.15; p= 0.003) and no changes in Creb mRNA levels (+6%, t(8)= 0.65; p= 
0.53). X) Activation of the aCaMKII is reduced in the PFC homogenate of DAT-KO rats (-30%, 
t(8)= 3.30; p= 0.011). X) The trascriptional changes of BDNF were paralleled by a reduction in the 
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mature form of BDNF (mBDNF) levels (-30%, t(8)= 3.12; p= 0.014) and accompanied by reduced 
activation of trkB (-30%, t(8)= 2.38; p= 0.044) in the PFC homogenate of DAT-KO rats. X) In the 
dorsolateral striatum (DLStr), mBDNF levels are increased in the homogenate and in the cytosol 
while reduced in the post-synaptic density (homogenate: +143%, t(7)= 9.56; p< 0.0001; cytosol: 
+78%, t(7)= 2.59; p= 0.036; post-synaptic density: -20%, t(8)= 2.53; p= 0.035). X) trkB activation is 
reduced in the post-synaptic density of DLStr (-15%, t(8)= 2.38; p= 0.045). X) PSD-95 is reduced in 
the post-synaptic density of DLStr of DAT-KO rats (-21%, t(8)= 2.57; p= 0.033). 
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